HDL Nanodiscs Loaded with Liver X Receptor Agonist Decreases Tumor Burden and Mediates Long‐term Survival in Mouse Glioma Model
Small · 2025
DOI: 10.1002/smll.202307097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2025. Verfasst von Troy A Halseth und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, 428 Church St, Ann Arbor, MI, 48109, USA. Hauptthemen laut MEDLINE: Liver X Receptors, Lipoproteins, HDL, Glioma, Tumor Burden. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Glioblastoma multiforme (GBM) is a highly aggressive primary brain tumor with a 5‐year survival rate of 7%. Previous studies have shown that GBM tumors have a reduced capacity to produce cholesterol and instead depend on the uptake of cholesterol produced by astrocytes. To target cholesterol metabolism to induce cancer cell death, synthetic high‐density lipoprotein (sHDL) nanodiscs delivering Liver‐X‐Receptor (LXR) agonists and CpG oligonucleotides for targeting GBM are investigated. LXR agonists synergize with sHDL nanodiscs by increasing the expression of the ABCA1 cholesterol efflux transporter, resulting in further depletion of cholesterol reserves within tumors, and CpG oligonucleotides are established adjuvants used in cancer immunotherapy that work through the toll‐like receptor 9 pathway. In the present study, treatment with GW‐CpG‐sHDL nanodiscs increases the expression of cholesterol efflux transporters on murine GL261 cells leading to enhanced cholesterol removal. Experiments in GL261‐tumor‐bearing mice reveal combining GW‐CpG‐sHDL nanodiscs with radiation (IR) therapy significantly increases median survival compared to GW‐CpG‐sHDL or IR alone. Furthermore, 66% of long‐term survivors from the GW‐CpG‐sHDL +IR treatment group show no tumor tissue when rechallenged.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, 428 Church St, Ann Arbor, MI, 48109, USA.
- Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, Michigan, 48109, USA.
- Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
- Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, 428 Church St, Ann Arbor, MI, 48109, USA.
- Engineering Research Center for Pharmaceuticals and Equipment of Sichuan Province, Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University, Chengdu, 610106, China.
ORCID-Profile: Anna Schwendeman
Förderung
- NINDS NIH HHS
- NIH HHS
- NHLBI NIH HHS
- Leah's Happy Hearts
- Pharmaceutical Research and Manufacturers of America Foundation
- Ian's Friends Foundation
- Smiles for Sophie Forever Foundation
- ChadTough Foundation
Zitieren
APA
Halseth, T. A., Mujeeb, A. A., Liu, L., Banerjee, K., Lang, N., Hollon, T., Yu, M., Vander Roest, M., Mei, L., He, H., Sheth, M., Castro, M. G., & Schwendeman, A. (2025). HDL Nanodiscs Loaded with Liver X Receptor Agonist Decreases Tumor Burden and Mediates Long‐term Survival in Mouse Glioma Model. Small. https://doi.org/10.1002/smll.202307097
Vancouver
Halseth TA, Mujeeb AA, Liu L, Banerjee K, Lang N, Hollon T, et al. HDL Nanodiscs Loaded with Liver X Receptor Agonist Decreases Tumor Burden and Mediates Long‐term Survival in Mouse Glioma Model. Small. 2025. doi:10.1002/smll.202307097
BibTeX
@article{Halseth2025,
author = {Halseth, Troy A and Mujeeb, Anzar A and Liu, Lisha and Banerjee, Kaushik and Lang, Nigel and Hollon, Todd and Yu, Minzhi and Vander Roest, Mark and Mei, Ling and He, Hongliang and Sheth, Maya and Castro, Maria G and Schwendeman, Anna},
title = {HDL Nanodiscs Loaded with Liver X Receptor Agonist Decreases Tumor Burden and Mediates Long‐term Survival in Mouse Glioma Model},
journal = {Small},
year = {2025},
doi = {10.1002/smll.202307097}
}
EUVIMED